Acridones circumvent P-glycoprotein-associated multidrug resistance (MDR) in cancer cells

Vadiraj S Gopinath1, Padma Thimmaiah, Kuntebommanahalli N Thimmaiah

  • 1Advinus Therapeutic Pvt. Ltd, 21 & 22, Phase-II, Peenya Industrial Area, Bangalore 560 058, India. vadiraj.gopinath@advinus.com

Insights

Researchers synthesized novel 2-chloroacridone analogs to combat multidrug resistance (MDR) in cancer. Several compounds effectively increased chemotherapy drug uptake and reversed resistance by inhibiting P-glycoprotein (P-gp), showing promise as chemosensitizers.

Area of Science:

  • Medicinal Chemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) mediated by P-glycoprotein (P-gp) overexpression is a major challenge in cancer chemotherapy.
  • Chemosensitizers can restore the efficacy of chemotherapeutic agents in MDR cancer cells.

Purpose of the Study:

  • To synthesize and evaluate novel N(10)-substituted-2-chloroacridone analogs as potential chemosensitizers.
  • To investigate the mechanism of action of these compounds in overcoming MDR.

Main Methods:

  • Synthesis of N(10)-substituted-2-chloroacridone analogs via Ullmann condensation and nucleophilic substitution.
  • Determination of lipophilicity (log(10)P) and pK(a).
  • Assays for vinblastine (VLB) uptake, VLB efflux inhibition, and [(3)H]azidopine binding to P-gp.
  • Evaluation of cytotoxicity modulation and reversal of VLB resistance.

Main Results:

  • Compounds 6, 8, 11-14, 16, and 17 significantly increased VLB accumulation in MDR cells compared to verapamil.
  • These modulators inhibited VLB efflux and competed with [(3)H]azidopine for P-gp binding, indicating P-gp as the target.
  • Modulators 11, 13, 14, 16, and 17 completely reversed a 25-fold resistance to VLB.
  • Lipophilicity correlated with MDR modulating activity.

Conclusions:

  • Novel 2-chloroacridone analogs demonstrate significant potential as chemosensitizers to overcome P-gp-mediated MDR.
  • Hydrophobicity is a key determinant for the anti-MDR activity of these compounds.
  • Further structural optimization could lead to more potent MDR modulators for cancer therapy.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...